1.1 List of Tables 9
1.2 List of Figures 12
2 Introduction 15
2.1 What is This Report About? 15
3 In Vitro Diagnostics In Belgium 16
3.1 In Vitro Diagnostics, Market Segmentation 16
3.2 In Vitro Diagnostics, Belgium, Overall Revenue ($m), USD Actual, 2003-2017
17
3.3 In Vitro Diagnostics Market, Belgium, Revenue Mix ($m), 2010 19
3.4 In Vitro Diagnostics Market, Belgium, Category Contribution (%), 2010 20
3.5 In Vitro Diagnostics, Belgium, Company share (2009-2010) 27
4 Clinical Chemistry In Belgium 29
4.1 Clinical Chemistry, Market Segmentation 29
4.2 Clinical Chemistry Market, Belgium, Revenue Mix ($m), 2010 30
4.3 Clinical Chemistry Market, Belgium, Segment Contribution (%), 2010 31
4.4 Clinical Chemistry Overall Revenue (2003-2017) 32
4.4.1 Clinical Chemisty Analyzers Revenue (2003-2017) 36
4.4.2 Urine Analysis Revenue (2003-2017) 40
4.5 Clinical Chemistry Distribution Share (2009-2010) 44
4.6 Clinical Chemistry, Belgium, Company share (2009-2010) 45
5 Genetic Testing In Belgium 47
5.1 Genetic Testing, Market Segmentation 47
5.2 Genetic Testing Market, Belgium, Revenue Mix ($m), 2010 48
5.3 Genetic Testing Market, Belgium, Segment Contribution (%), 2010 49
5.4 Genetic Testing Overall Revenue (2003-2017) 50
5.5 Genetic Testing Distribution Share (2009-2010) 54
5.6 Genetic Testing, Belgium, Company share (2009-2010) 55
6 Haematology In Belgium 57
6.1 Haematology, Market Segmentation 57
6.2 Haematology Market, Belgium, Revenue Mix ($m), 2010 58
6.3 Haematology Market, Belgium, Segment Contribution (%), 2010 59
6.4 Haematology Overall Revenue (2003-2017) 60
6.4.1 Haematology Reagents Revenue (2003-2017) 64
6.4.2 Immunohaematology Revenue (2003-2017) 68
6.4.3 Haemostasis Revenue (2003-2017) 72
6.4.4 Haematology Rapid Tests Revenue (2003-2017) 76
6.4.5 Haematology Cell Counters Revenue (2003-2017) 80
6.5 Haematology Distribution Share (2009-2010) 84
6.6 Haematology, Belgium, Company Share (2009-2010) 85
7 Histology And Cytology In Belgium 87
7.1 Histology And Cytology, Market Segmentation 87
7.2 Histology And Cytology Market, Belgium, Revenue Mix ($m), 2010 88
7.3 Histology And Cytology Market, Belgium, Segment Contribution (%), 2010 89
7.4 Histology And Cytology Overall Revenue (2003-2017) 90
7.5 Histology And Cytology Distribution Share (2009-2010) 94
7.6 Histology And Cytology, Belgium, Company share (2009-2010) 95
8 Immuno Chemistry In Belgium 97
8.1 Immuno Chemistry Market, Belgium, Revenue Mix ($m), 2010 97
8.2 Immuno Chemistry Market, Belgium, Segment Contribution (%), 2010 98
8.3 Immuno Chemistry Overall Revenue (2003-2017) 99
8.3.1 Disease Specific Immunochemistry Revenue (2003-2017) 103
8.3.2 Drugs of Abuse / Toxicology Revenue (2003-2017) 107
8.3.3 Endocrinology Tests Revenue (2003-2017) 111
8.3.4 Therapeutic Drug Monitoring Revenue (2003-2017) 115
8.3.5 Immunochemistry Analyzers Revenue (2003-2017) 119
8.4 Immuno Chemistry Distribution Share (2009-2010) 123
8.5 Immuno Chemistry, Belgium, Company share (2009-2010) 124
9 Infectious Immunology In Belgium 126
9.1 Infectious Immunology, Market Segmentation 126
9.2 Infectious Immunology Market, Belgium, Revenue Mix ($m), 2010 127
9.3 Infectious Immunology Market, Belgium, Segment Contribution (%), 2010 128
9.4 Infectious Immunology Overall Revenue (2003-2017) 129
9.5 Infectious Immunology Distribution Share (2009-2010) 133
9.6 Infectious Immunology, Belgium, Company share (2009-2010) 134
10 Microbiology Culture In Belgium 136
10.1 Microbiology Culture, Market Segmentation 136
10.2 Microbiology Culture Market, Belgium, Revenue Mix ($m), 2010 137
10.3 Microbiology Culture Market, Belgium, Segment Contribution (%), 2010 138
10.4 Microbiology Culture Overall Revenue (2003-2017) 139
10.4.1 Microbiology Analyzers Revenue (2003-2017) 143
10.5 Microbiology Culture Distribution Share (2009-2010) 147
10.6 Microbiology Culture, Belgium, Company share (2009-2010) 148
11 Overview of Key Companies in Belgium In Vitro Diagnostics Market 150
11.1 F. Hoffmann-La Roche Ltd. 150
11.1.1 Company Overview 150
11.1.2 Share in the Belgium In Vitro Diagnostics Market 150
11.2 Siemens Healthcare 151
11.2.1 Company Overview 151
11.2.2 Share in the Belgium In Vitro Diagnostics Market 151
11.3 Abbott Laboratories 152
11.3.1 Company Overview 152
11.3.2 Share in the Belgium In Vitro Diagnostics Market 152
11.4 bioMerieux S.A. 153
11.4.1 Company Overview 153
11.4.2 Share in the Belgium In Vitro Diagnostics Market 153
11.5 Ortho-Clinical Diagnostics Inc. 154
11.5.1 Company Overview 154
11.5.2 Share in the Belgium In Vitro Diagnostics Market 154
11.6 Beckman Coulter, Inc. 155
11.6.1 Company Overview 155
11.6.2 Share in the Belgium In Vitro Diagnostics Market 155
11.7 Bio-Rad Laboratories, Inc. 156
11.7.1 Company Overview 156
11.8 Sysmex Corporation 156
11.8.1 Company Overview 156
11.9 Becton, Dickinson and Company 156
11.9.1 Company Overview 156
11.10 Phadia AB 157
11.10.1 Company Overview 157
11.11 DiaSorin S.p.A 157
11.11.1 Company Overview 157
11.12 Qiagen N.V. 157
11.12.1 Company Overview 157
11.13 DIAGNOSTICA STAGO, Inc. 158
11.13.1 Company Overview 158
11.14 Gen-Probe Incorporated 158
11.14.1 Company Overview 158
11.15 Grifols, S.A. 158
11.15.1 Company Overview 158
11.16 Alere Inc. 159
11.16.1 Company Overview 159
11.17 Thermo Fisher Scientific Inc. 159
11.17.1 Company Overview 159
11.18 HORIBA, Ltd. 159
11.18.1 Company Overview 159
11.19 PerkinElmer, Inc. 160
11.19.1 Company Overview 160
11.20 Danaher Corporation 160
11.20.1 Company Overview 160
11.21 The Elitech Group 160
11.21.1 Company Overview 160
11.22 Life Technologies Corporation 161
11.22.1 Company Overview 161
11.23 Immucor, Inc. 161
11.23.1 Company Overview 161
11.24 Hologic, Inc. 161
11.24.1 Company Overview 161
12 In Vitro Diagnostics Market Pipeline Products 163
12.1 Clinical Chemisty Market Pipeline Products 163
12.2 Immuno Chemistry Market Pipeline Products 166
12.3 Haematology Market Pipeline Products 169
12.4 Infectious Immunology Market Pipeline Products 171
12.5 Microbiology Culture Market Pipeline Products 175
12.6 Histology and Cytology Market Pipeline Products 176
12.7 Genetic Testing Market Pipeline Products 177
13 Financial Deals Landscape 182
13.1 Partnerships 182
13.1.1 Life Technologies Enters Into Co-Development Agreement With
GlaxoSmithKline Biologicals 182
13.1.2 Skyline Diagnostics Enters Into Research Collaboration With Johnson &
Johnson Pharmaceutical 183
13.1.3 BD Diagnostic Enters Into Co-Development Agreement With Diagenode 184
13.1.4 Trinity Biotech Enters Into Distribution Agreement With A. Menarini
Diagnostics 185
13.1.5 ImaginAb Enters Into Collaboration With Eurogentec 186
13.1.6 MDxHealth Enters Into Licensing Agreement With Exact Sciences 187
14 Recent Developments 188
14.1 Strategy And Business Planning 188
14.1.1 Nov 16, 2011: DOCS Continues Expansion With Four New Offices In Europe
188
14.1.2 Mar 18, 2011: Volition Opens Belgian Office And Lab Facilities In Namur,
Wallonia 188
14.2 Government and Public Interest 189
14.2.1 Jul 26, 2011: Ablynx Receives GLP Certificate For New GLP Unit 189
14.3 Product News 189
14.3.1 Mar 22, 2011: DIAsource ImmunoAssays Launches New 25OH Vitamin D Total
RIA Test 189
15 Appendix 190
15.1 Definitions of Markets Covered in the Report 191
15.1.1 In Vitro Diagnostics 191
15.2 Research Methodology 202
15.3 Secondary Research 202
15.4 Primary Research 202
15.5 Models 203
15.6 Forecasts 204
15.7 Expert Panels 204
15.8 GlobalData Consulting 204
15.9 Currency Conversion 205
15.10 Contact Us 205
15.11 Disclaimer 205
1.1 List of Tables
Table 1: In Vitro Diagnostics, Belgium, Overall Revenue ($m), USD Actual,
2003-2017 18
Table 2: In Vitro Diagnostics Market, Belgium, Category Contribution (%), 2010
20
Table 3: In Vitro Diagnostics, Belgium, Cross-Category Analysis, 2003-2017 22
Table 4: In Vitro Diagnostics, Belgium, Overall Revenue ($m), USD Actual,
Historic, 2003-2010 24
Table 5: In Vitro Diagnostics, Belgium, Overall Revenue ($m), USD Actual,
Forecast, 2010-2017 26
Table 6: In Vitro Diagnostics, Belgium, Company share by Revenue ($m), USD
Actual, 2009-2010 28
Table 7: Clinical Chemistry Market, Belgium, Segment Contribution (%), 2010 31
Table 8: Clinical Chemistry, Belgium, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 33
Table 9: Clinical Chemistry, Belgium, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 35
Table 10: Clinical Chemisty Analyzers, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 37
Table 11: Clinical Chemisty Analyzers, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 39
Table 12: Urine Analysis, Belgium, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 41
Table 13: Urine Analysis, Belgium, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 43
Table 14: Clinical Chemistry, Belgium, Distribution Share by Revenue ($m), USD
Actual, 2009-2010 44
Table 15: Clinical Chemistry, Belgium, Company share by Revenue ($m), USD Actual
2009-2010 46
Table 16: Genetic Testing Market, Belgium, Segment Contribution (%), 2010 49
Table 17: Genetic Testing, Belgium, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 51
Table 18: Genetic Testing, Belgium, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 53
Table 19: Genetic Testing, Belgium, Distribution Share by Revenue ($m), USD
Actual, 2009-2010 54
Table 20: Genetic Testing, Belgium, Company Share by Revenue ($m), USD Actual
2009-2010 56
Table 21: Haematology Market, Belgium, Segment Contribution (%), 2010 59
Table 22: Haematology, Belgium, Revenue ($m), USD Actual by Segment, Historic,
2003-2010 61
Table 23: Haematology, Belgium, Revenue ($m), USD Actual by Segment, Forecast,
2010-2017 63
Table 24: Haematology Reagents, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 65
Table 25: Haematology Reagents, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 67
Table 26: Immunohaematology, Belgium, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 69
Table 27: Immunohaematology, Belgium, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 71
Table 28: Haemostasis, Belgium, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 73
Table 29: Haemostasis, Belgium, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 75
Table 30: Haematology Rapid Tests, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 77
Table 31: Haematology Rapid Tests, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 79
Table 32: Haematology Cell Counters, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 81
Table 33: Haematology Cell Counters, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 83
Table 34: Haematology, Belgium, Distribution Share by Revenue ($m), USD Actual,
2009-2010 84
Table 35: Haematology, Belgium, Company share by Revenue ($m), USD Actual
2009-2010 86
Table 36: Histology And Cytology Market, Belgium, Segment Contribution (%), 2010
89
Table 37: Histology And Cytology, Belgium, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 91
Table 38: Histology And Cytology, Belgium, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 93
Table 39: Histology And Cytology, Belgium, Distribution Share by Revenue ($m),
USD Actual, 2009-2010 94
Table 40: Histology And Cytology, Belgium, Company share by Revenue ($m), USD
Actual 2009-2010 96
Table 41: Immuno Chemistry Market, Belgium, Segment Contribution (%), 2010 98
Table 42: Immuno Chemistry, Belgium, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 100
Table 43: Immuno Chemistry, Belgium, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 102
Table 44: Disease Specific Immunochemistry, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 104
Table 45: Disease Specific Immunochemistry, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 106
Table 46: Drugs of Abuse / Toxicology, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 108
Table 47: Drugs of Abuse / Toxicology, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 110
Table 48: Endocrinology Tests, Belgium, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 112
Table 49: Endocrinology Tests, Belgium, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 114
Table 50: Therapeutic Drug Monitoring, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 116
Table 51: Therapeutic Drug Monitoring, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 118
Table 52: Immunochemistry Analyzers, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 120
Table 53: Immunochemistry Analyzers, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 122
Table 54: Immuno Chemistry, Belgium, Distribution Share by Revenue ($m), USD
Actual, 2009-2010 123
Table 55: Immuno Chemistry, Belgium, Company share by Revenue ($m), USD Actual
2009-2010 125
Table 56: Infectious Immunology Market, Belgium, Segment Contribution (%), 2010
128
Table 57: Infectious Immunology, Belgium, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 130
Table 58: Infectious Immunology, Belgium, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 132
Table 59: Infectious Immunology, Belgium, Distribution Share by Revenue ($m),
USD Actual, 2009-2010 133
Table 60: Infectious Immunology, Belgium, Company share by Revenue ($m), USD
Actual 2009-2010 135
Table 61: Microbiology Culture Market, Belgium, Segment Contribution (%), 2010
138
Table 62: Microbiology Culture, Belgium, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 140
Table 63: Microbiology Culture, Belgium, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 142
Table 64: Microbiology Analyzers, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 144
Table 65: Microbiology Analyzers, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 146
Table 66: Microbiology Culture, Belgium, Distribution Share by Revenue ($m), USD
Actual, 2009-2010 147
Table 67: Microbiology Culture, Belgium, Company share by Revenue ($m), USD
Actual 2009-2010 149
Table 68: Clinical Chemisty Market Pipeline Products 163
Table 69: Immuno Chemistry Market Pipeline Products 166
Table 70: Haematology Market Pipeline Products 169
Table 71: Infectious Immunology Market Pipeline Products 171
Table 72: Microbiology Culture Market Pipeline Products 175
Table 73: Histology and Cytology Market Pipeline Products 176
Table 74: Genetic Testing Market Pipeline Products 177
Table 75: Life Technologies Enters Into Co-Development Agreement With
GlaxoSmithKline Biologicals 182
Table 76: Skyline Diagnostics Enters Into Research Collaboration With Johnson &
Johnson Pharmaceutical 183
Table 77: BD Diagnostic Enters Into Co-Development Agreement With Diagenode 184
Table 78: Trinity Biotech Enters Into Distribution Agreement With A. Menarini
Diagnostics 185
Table 79: ImaginAb Enters Into Collaboration With Eurogentec 186
Table 80: MDxHealth Enters Into Licensing Agreement With Exact Sciences 187
Table 81: USD to Local Currency, Belgium, Average Actual Rate 2003-2010 205
1.2 List of Figures
Figure 1: In Vitro Diagnostics, Market Segmentation 16
Figure 2: In Vitro Diagnostics, Belgium, Overall Revenue ($m), USD Actual,
2003-2017 17
Figure 3: In Vitro Diagnostics Market, Belgium, Revenue Mix ($m), 2010 19
Figure 4: In Vitro Diagnostics Market, Belgium, Category Contribution (%), 2010
20
Figure 5: In Vitro Diagnostics, Belgium, Cross-Category Analysis, 2003-2017 21
Figure 6: In Vitro Diagnostics, Belgium, Overall Revenue ($m), USD Actual,
Historic, 2003-2010 23
Figure 7: In Vitro Diagnostics, Belgium, Overall Revenue ($m), USD Actual,
Forecast, 2010-2017 25
Figure 8: In Vitro Diagnostics, Belgium, Company share (%), 2010 27
Figure 9: Clinical Chemistry, Market Segmentation 29
Figure 10: Clinical Chemistry Market, Belgium, Revenue Mix ($m), 2010 30
Figure 11: Clinical Chemistry Market, Belgium, Segment Contribution (%), 2010 31
Figure 12: Clinical Chemistry, Belgium, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 32
Figure 13: Clinical Chemistry, Belgium, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 34
Figure 14: Clinical Chemisty Analyzers, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 36
Figure 15: Clinical Chemisty Analyzers, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 38
Figure 16: Urine Analysis, Belgium, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 40
Figure 17: Urine Analysis, Belgium, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 42
Figure 18: Clinical Chemistry, Belgium, Company share (%), 2010 45
Figure 19: Genetic Testing, Market Segmentation 47
Figure 20: Genetic Testing Market, Belgium, Revenue Mix ($m), 2010 48
Figure 21: Genetic Testing Market, Belgium, Segment Contribution (%), 2010 49
Figure 22: Genetic Testing, Belgium, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 50
Figure 23: Genetic Testing, Belgium, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 52
Figure 24: Genetic Testing, Belgium, Company Share (%), 2010 55
Figure 25: Haematology, Market Segmentation 57
Figure 26: Haematology Market, Belgium, Revenue Mix ($m), 2010 58
Figure 27: Haematology Market, Belgium, Segment Contribution (%), 2010 59
Figure 28: Haematology, Belgium, Revenue ($m), USD Actual by Segment, Historic,
2003-2010 60
Figure 29: Haematology, Belgium, Revenue ($m), USD Actual by Segment, Forecast,
2010-2017 62
Figure 30: Haematology Reagents, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 64
Figure 31: Haematology Reagents, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 66
Figure 32: Immunohaematology, Belgium, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 68
Figure 33: Immunohaematology, Belgium, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 70
Figure 34: Haemostasis, Belgium, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 72
Figure 35: Haemostasis, Belgium, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 74
Figure 36: Haematology Rapid Tests, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 76
Figure 37: Haematology Rapid Tests, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 78
Figure 38: Haematology Cell Counters, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 80
Figure 39: Haematology Cell Counters, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 82
Figure 40: Haematology, Belgium, Company Share (%), 2010 85
Figure 41: Histology And Cytology, Market Segmentation 87
Figure 42: Histology And Cytology Market, Belgium, Revenue Mix ($m), 2010 88
Figure 43: Histology And Cytology Market, Belgium, Segment Contribution (%),
2010 89
Figure 44: Histology And Cytology, Belgium, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 90
Figure 45: Histology And Cytology, Belgium, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 92
Figure 46: Histology And Cytology, Belgium, Company Share (%), 2010 95
Figure 47: Immuno Chemistry Market, Belgium, Revenue Mix ($m), 2010 97
Figure 48: Immuno Chemistry Market, Belgium, Segment Contribution (%), 2010 98
Figure 49: Immuno Chemistry, Belgium, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 99
Figure 50: Immuno Chemistry, Belgium, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 101
Figure 51: Disease Specific Immunochemistry, Belgium, Revenue ($m), USD Actual
by Sub-Segment, Historic, 2003-2010 103
Figure 52: Disease Specific Immunochemistry, Belgium, Revenue ($m), USD Actual
by Sub-Segment, Forecast, 2010-2017 105
Figure 53: Drugs of Abuse / Toxicology, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 107
Figure 54: Drugs of Abuse / Toxicology, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 109
Figure 55: Endocrinology Tests, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 111
Figure 56: Endocrinology Tests, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 113
Figure 57: Therapeutic Drug Monitoring, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 115
Figure 58: Therapeutic Drug Monitoring, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 117
Figure 59: Immunochemistry Analyzers, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 119
Figure 60: Immunochemistry Analyzers, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 121
Figure 61: Immuno Chemistry, Belgium, Company share (%), 2010 124
Figure 62: Infectious Immunology, Market Segmentation 126
Figure 63: Infectious Immunology Market, Belgium, Revenue Mix ($m), 2010 127
Figure 64: Infectious Immunology Market, Belgium, Segment Contribution (%), 2010
128
Figure 65: Infectious Immunology, Belgium, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 129
Figure 66: Infectious Immunology, Belgium, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 131
Figure 67: Infectious Immunology, Belgium, Company Share (%), 2010 134
Figure 68: Microbiology Culture, Market Segmentation 136
Figure 69: Microbiology Culture Market, Belgium, Revenue Mix ($m), 2010 137
Figure 70: Microbiology Culture Market, Belgium, Segment Contribution (%), 2010
138
Figure 71: Microbiology Culture, Belgium, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 139
Figure 72: Microbiology Culture, Belgium, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 141
Figure 73: Microbiology Analyzers, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 143
Figure 74: Microbiology Analyzers, Belgium, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 145
Figure 75: Microbiology Culture, Belgium, Company share (%), 2010 148
Figure 76: F. Hoffmann-La Roche Ltd., Company Share (%),Belgium In Vitro
Diagnostics Market, 2010 150
Figure 77: Siemens Healthcare, Company Share (%),Belgium In Vitro Diagnostics
Market, 2010 151
Figure 78: Abbott Laboratories, Company Share (%),Belgium In Vitro Diagnostics
Market, 2010 152
Figure 79: bioMerieux S.A., Company Share (%),Belgium In Vitro Diagnostics
Market, 2010 153
Figure 80: Ortho-Clinical Diagnostics Inc., Company Share (%),Belgium In Vitro
Diagnostics Market, 2010 154
Figure 81: Beckman Coulter, Inc., Company Share (%),Belgium In Vitro Diagnostics
Market, 2010 155
Companies Mentioned :
F. Hoffmann-La Roche Ltd.
Siemens Healthcare
Abbott Laboratories
bioMerieux S.A.
Ortho-Clinical Diagnostics Inc.
Beckman Coulter, Inc.
Bio-Rad Laboratories, Inc.
Sysmex Corporation
Becton, Dickinson and Company
Phadia AB
DiaSorin S.p.A
Qiagen N.V.
DIAGNOSTICA STAGO, Inc.
Gen-Probe Incorporated
Grifols, S.A.
Alere Inc.
Thermo Fisher Scientific Inc.
HORIBA, Ltd.
PerkinElmer, Inc.
Danaher Corporation
The Elitech Group
Life Technologies Corporation
Immucor, Inc.
Hologic, Inc.
|
